Everything journalists need to cover The Reversal Initiative. Story angles, assets, and direct contact information.
The Neurodegenerative Reversal Research Foundation (incorporation in progress) funds wet-lab tests of Alzheimer's hypotheses at outside laboratories: $100,000 funds one complete test. Our key application is Alzheimer's reversal, within the broader area of drug design and biological discovery. The Foundation was started by David Scott Lewis (President; former EVP, META Group, now part of Gartner), with Enrique Zueco (Treasurer) and Haley Yi (Secretary). We publish what we learn, including negative results.
The project follows the Pieper lab's 2025 Cell Reports Medicine paper (DOI: 10.1016/j.xcrm.2025.102535) from Case Western Reserve / Harrington Discovery Institute, which demonstrated that P7C3-A20, an NAD+ pathway activator, reversed Alzheimer's pathology in mice. The Foundation exists to fund the bridge between preclinical findings like this one and potential human therapies — across multiple AD compounds and pathways.
The team has 16 certified AAIC 2026 posters (Alzheimer's Association International Conference, London) and 29 papers accepted at NeurIPS 2026 workshops, with prior Alzheimer-specific papers at ICLR 2026 workshops covering genomics, drug-discovery, and biomedical-reasoning, and work at AAAI-26 — 54 accepted workshop papers at major venues total (public on OpenReview). Its hypotheses are ready for their first wet-lab tests.
David Scott Lewis has seen the disease up close. Now he's building the computational tools he wished had existed — and making them available to academic labs that can't afford enterprise platforms.
Scientists reversed Alzheimer's in mice. A European computational-biology team is building the bridge to human therapies through a 37-module platform offered to academic and foundation-funded research partners.
The team publishes results openly. Follow the computational hypotheses as they are tested — from in-silico screens to the wet-lab validation stage.
Why locking research tools behind $500K enterprise contracts slows down the fight against the world's most costly disease — and what a partnership-access model can change.
Why $100,000 funds one complete wet-lab test at an outside laboratory, and why the Foundation publishes every result, including negative ones.
High-resolution founder photos and team imagery (coming soon)
Initiative and AIXC logos in SVG, PNG, and EPS formats (coming soon)
Single-page summary with key facts and figures (coming soon)
For interviews, comments, or additional information:
enrique.zueco@alzheimersreversal.org
We typically respond to press inquiries within 12 hours.
Get the complete media package including high-res assets, fact sheet, founder bios, and interview availability.
Request Press Kit